<SEC-DOCUMENT>0001558370-21-001407.txt : 20210223
<SEC-HEADER>0001558370-21-001407.hdr.sgml : 20210223
<ACCEPTANCE-DATETIME>20210223070135
ACCESSION NUMBER:		0001558370-21-001407
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210223
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210223
DATE AS OF CHANGE:		20210223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		21663022

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20210223x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/23/2021 12:01:19 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: 418fc221-2484-4911-a599-fd61edb7c47a -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20210223" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityCentralIndexKey" id="Tc_1nsKhS4p3UGjAmBFLAY_Kg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:AmendmentFlag" id="Tc_BGWTED7tykauGVSulTz3sQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20210223.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-23</xbrli:startDate><xbrli:endDate>2021-02-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_66e6d4a8_9435_4cc8_9e61_2e7ee2b3d21b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:DocumentType" id="Narr_zhrRaXm2P0CPqBvRtevE0w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_RbKN5T7o-EG2f9iW9x2fHg"><b style="font-weight:bold;">February&#160;23, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityRegistrantName" id="Narr_Rh3QZzYL00CcEPWqzxA4mA"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_90d56288_4b42_4075_a557_1ea8f44584d5"></a><a id="Tc_DhDk-gLfCkibUYCJxm5yQA_1_0"></a><a id="Tc_swBayoqvKUuzASBm5SaTvA_1_2"></a><a id="Tc_wmr0gFLnHkq_pQYQhYrTjA_1_4"></a><a id="Tc_nUcH2wrun0uEgY9uuQ_Ktg_5_0"></a><a id="Tc_z_gQzST6NUyM97yQggexzg_6_0"></a><a id="Tc_klvEvVbN_0aHw2SEuA_UeA_6_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_gw-3MT-dH0a5aJ2ZA8Pngw_0_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityFileNumber" id="Tc_iEoNX6d_406ylrWyl9nvlA_0_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityTaxIdentificationNumber" id="Tc_XhcHPPhAG06NgJQHvALf0Q_0_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer<br />Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityAddressAddressLine1" id="Tc_k7Wv8i8zDUiNy059Y6ga2Q_3_0"><b style="font-weight:bold;">2 Snunit Street</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityAddressAddressLine2" id="Tc_g-alXcnZdESXLQTDrj738Q_4_0"><b style="font-weight:bold;">Science Park, POB 455</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityAddressCityOrTown" id="Narr_ydDTsa2-qUS6ZTT1TYZgKA"><b style="font-weight:bold;">Carmiel</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="Narr_oquK1Wyl7U2U61YVYFhC-w"><b style="font-weight:bold;">Israel</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:EntityAddressPostalZipCode" id="Tc_CmCgRNitN02IlwUt7Yb7Dg_5_4"><b style="font-weight:bold;">2161401</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code +</b><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:CityAreaCode" id="Narr_5VMagqk5FEyKG-X233Zj8Q"><b style="font-weight:bold;">972-4</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:LocalPhoneNumber" id="Narr_agM8SDy8EUugWleHBjy7bg"><b style="font-weight:bold;">988-9488</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_7Q0pKDIn7kaCBomAlnHP0w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_OQzerhduw0elgA5g4r8D7A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_LlwwebT99EWir3n2BnSeiw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_kJ2UqQqUfE-nGjnjlM2x0w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_AKmtSj8uIkmUNdyKCl7e8g_1_0"></a><a id="Tc_nbOVbRUG_U2bzJ9z9XDbAA_1_1"></a><a id="Tc_u6DNeJaHo0y8eV3q_sOKdw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:Security12bTitle" id="Tc_eDokBOTHqUCLh7Yaoox2zw_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" name="dei:TradingSymbol" id="Tc_lqiXCmV2D0mGXfhWQ04xHA_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_eJg70SAC0ESS_HoOlRIKEA_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_nJXQIXw_5kSF3sg0Jqc-5g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February&#160;23, 2021, Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing positive topline results from the BRIGHT Phase&#160;III clinical trial evaluating pegunigalsidase alfa (PRX-102), 2&#160;mg/kg, administered every four weeks, for the potential treatment of Fabry disease. PRX-102 is the Company&#8217;s plant cell-expressed recombinant, PEGylated, cross-linked &#945;-galactosidase-A product candidate. A copy of the press release is attached as Exhibit&#160;99.1 to this Current Report on Form 8<span style="color:#333333;">-</span>K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a style="-sec-extract:exhibit;" href="plx-20210223xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release dated February&#160;23, 2021</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="background-color:#ffffff;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February&#160;23, 2021</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20210223xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 2/23/2021 12:01:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="plx-20210223xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:134.98pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="plx-20210223xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:47.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:132pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase&#160;III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2&#160;mg/kg every Four Weeks for Treatment of Fabry Disease<br></b><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Study achieved key objectives for safety, efficacy and pharmacokinetics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">After completion of the study, all patients enrolled in an extension study </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">pegunigalsidase alfa (PRX-102) provided coverage to patients for the entire 4-week period in treated patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">No new patients developed treatment-induced anti-drug antibodies following switch to PRX-102</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Third clinical study to demonstrate positive outcome in support of PRX-102, with data from PB-102-F01 and F02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Phase I/II clinical trials and BRIDGE studies previously announced<br></i><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CARMIEL, Israel</b>, February&#160;23, 2021 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research focused healthcare Group (Chiesi Group), today announced positive topline results from the BRIGHT Phase&#160;III clinical trial evaluating pegunigalsidase alfa (PRX-102), 2&#160;mg/kg, administered every four weeks, for the potential treatment of Fabry disease. PRX-102 is the Company&#8217;s plant cell-expressed recombinant, PEGylated, cross-linked &#945;-galactosidase-A product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The BRIGHT study is a Phase&#160;III 12-month, open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 treatment, 2&#160;mg/kg every four weeks, in up to 30&#160;patients with Fabry disease previously treated with a commercially available enzyme replacement therapy (ERT) (agalsidase alfa &#8211; Replagal<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup> or agalsidase beta &#8211; Fabrazyme<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>), for at least three years and on a stable dose administered every two weeks. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Topline results indicate that 2&#160;mg/kg of PRX-<a name="_Hlk64553510"></a>102 administered by intravenous infusion every four weeks was found to be well tolerated among treated patients, and stable clinical presentation was maintained in adult Fabry patients. No new patients developed treatment-induced anti-drug antibodies (ADA) following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;We are excited to share these topline results from the BRIGHT study, our third consecutive positive clinical trial of PRX-102, following the Phase I/II and the BRIDGE clinical studies. The results indicate that this investigational therapy is well tolerated and potentially an effective treatment for adult patients living with Fabry disease,&#8221; said Einat&#160;Brill&#160;Almon, Ph.D.,&#160;Protalix&#8217;s Senior Vice President and Chief Development Officer. &#8220;We are encouraged to see that all of the patients who completed this study chose to enroll in the long-term extension study. Currently, 80% of the patients enrolled in the BRIGHT study have been treated with this treatment regimen for over two years. We look forward to advancing this study and further evaluating the results.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;These results demonstrate the potential of PRX-102 to be an important treatment option for the Fabry community and that the 2&#160;mg/kg of PRX-102 every four&#160;weeks regimen may offer meaningful benefits to both patients and physicians. Treating physicians will be empowered with a potential additional treatment regimen, shown to be well tolerated, that they can offer to Fabry patients, pending approval of PRX-102,&#8221; said Dror Bashan,&#160;Protalix&#8217;s President and Chief Executive Officer. &#8220;We are gratified to have a strong balance sheet supporting our development efforts and look forward to executing and delivering on a year rich with value enhancing milestones.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The BRIGHT study enrolled 30&#160;adult patients (24&#160;males and 6&#160;females). The most common Fabry disease symptoms were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. All 30&#160;patients received at least one dose of PRX-102, and 29 patients (mean [SD] age was 40.5&#160;[11.3]&#160;years, ranging from 19 to 58&#160;years) completed the 12-month study. Of these 29 patients, 28 </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">received the intended regimen of 2&#160;mg/kg every four weeks throughout the study, while one patient was switched to PRX-102 1&#160;<a name="_Hlk64641068"></a>mg/kg every two weeks per protocol. One patient withdrew from the study after the first infusion due to a traffic accident. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following screening, patients were enrolled and switched from their then current ERT to intravenous (IV) infusions of 2&#160;mg/kg of PRX-102 every four weeks for 52 weeks (a total of 14&#160;infusions). First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures showed plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change of 3.01&#160;nM from baseline (19.36&#160;nM) to Week&#160;52 (22.23&#160;nM). Mean absolute change of eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;vertical-align:top;">2</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;Patients participating in the BRIGHT study have expressed their satisfaction with the once every four weeks regimen,&#8221; said John Bernat, M.D., Ph.D., University of Iowa and a Principal Investigator in the BRIGHT study. &#8220;Infusions of 2&#160;mg/kg once every four weeks has the potential to enable patients to maintain their clinical status while reducing their number of treatments by half.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory (BPI) questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;Of the 30 patients enrolled, 20 patients remained negative for anti-drug antibodies throughout the course of treatment. Of the 10 patients who were initially positive for anti-drug antibodies, four became negative for neutralizing antibodies at 12 months, suggesting tolerization by these patients,&#8221; added Dr. Almon. &#8220;We find this immunogenicity data very encouraging and supportive to the positive benefit-risk profile of PRX-102.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;On behalf of our team at Chiesi, we are grateful to the patients, families, and investigators for their time and participation in this study,&#8221; said Giacomo Chiesi, head of Chiesi Global Rare Diseases. &#8220;Their dedication has helped move this Phase III program forward and these topline data are another important milestone in our collected effort to make PRX-102 available to Fabry patients in need as rapidly as possible.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company intends to report final data on the BRIGHT study in the second half of 2021, and to present these findings at an appropriate medical conference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About Fabry Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal &#945;-Galactosidase-A enzyme&#160;resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>) in blood vessel walls throughout a person&#8217;s body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the &#945;-Galactosidase-A&#160;enzyme, which is normally responsible for the breakdown of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>&#160;increases with time and, accordingly, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>&#160;accumulates, primarily in the blood and in the blood vessel walls. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure &#8211; particularly of the kidneys, but also of the heart and the cerebrovascular system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About PRX-102</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant &#945;-Galactosidase-A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX-102 has been observed to have a circulatory half-life of approximately 80 hours. The Company designed PRX-102 to potentially address the continued unmet clinical need in Fabry patients.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human &#945;-Galactosidase-A protein for the proposed treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed USA, Inc. for the worldwide development and commercialization of PRX-110 for use in the treatment<font style="direction:rtl;">&#160;</font>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">About Chiesi Global Rare Diseases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. For more information visit&#160;www.chiesiglobalrarediseases.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&amp;D organization is headquartered in Parma (Italy), and is integrated with R&amp;D groups in France, the USA, the UK, and Sweden to advance Chiesi&#39;s pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi Group is a certified Benefit corporation. For more information, please visit www.chiesi.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: failure or delay in the commencement or completion of our preclinical and clinical trials which may be caused by several factors, including: risks that the FDA will not accept an application for accelerated approval of PRX-102 with the data generated to date or will request additional data or other conditions of our submission of any application for accelerated approval of PRX-102; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to monitor patients adequately during or after treatment; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and slower than expected rates of patient recruitment; risks associated with the novel coronavirus disease (COVID-19) outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">product candidates will not support our claims of safety or efficacy, that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; delays in the approval or potential rejection of any applications we file with the FDA or other health regulatory authorities, and other risks relating to the review process; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Investor Contact</b><font style="letter-spacing:-0.1pt;"><br></font><font style="letter-spacing:-0.1pt;">Chuck Padala, Managing Director<br>LifeSci Advisors<br>+1-646-627-8390<br></font><font style="color:#009ec2;letter-spacing:-0.1pt;">chuck@lifesciadvisors.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Source: Protalix BioTherapeutics, Inc.</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20210223xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210223xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? 0@# 2(  A$! Q$!_\0
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MUX\26.6))/4FNF\"2W:>(%2W!,3*?-';%=N-HJI2N]T>;EN(=*NDMI:'K1.
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FKK570JDAV0@]=HX_I16\B+&@1%"J!@ =J*X9RYG<]2G#DC8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20210223xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210223xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: 0X# 2(  A$! Q$!_\0
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M?96N<=.W%>\:;>1ZCIT%W$05E0,/QH N4SSHM^SS$W_W=PS2D=_2O+Q?7/\
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MBD4,CC!!KRC0[=_"OQ4FTQ"1:72&15[<]/YUZY7F.NLLWQ<TU8R"RQ_-C\*
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MZ=JX)L[A6(ZKT;\J;K'B#3]!\C[;,$\]MB>YKC=:AL[#QYHIT9$2YE?%PD/
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MWLMMHFG/?^4=KR@[4!]FP0: .OVJ/X1^5 50> ,UR>F^+S+J"6.K6<EA</\
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M&FG7.J^&+FTM%#3.!@&M;3XG@TZWC<894 (]Z .0NT%O\5K1H%P9;5S*!QG
M&/YUD:G=WW_"Q[EH-/%\T$(\J-B?D!P<C\:Z2]TF[F^(-CJ219M8X75Y,]#@
M8%'B3P_>/J4.N:.ZI?PC:Z'I*OI_*@"NWB#Q.P8-X;4J!@Y8X-96BVFIVJ^(
M9KFR6TMIXBXA!X5L'/TK2;7_ !/<1?9H=#\JXZ>8[ J/?K5W3/#ES8Z#?I<3
M&YO[I&+D]-Q'04 1_#JWBB\(V\B1A6DD<L1W.XU2T6..]^(NLS70#26JA(%;
M^!<]1^9K<\&Z?=:;X:M[6[39,K.2N?5B16=K^@ZA#K UW1'5;H*%EB;I*/\
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M )BC%+10 8%(12T4 8FD>'_[*U?4K[[1YGVV3?LVXV]/SZ5M8%+10 48HHH
@**** # HHHH ,4F*6B@!,48%+10 48HHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20210223.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2021 12:01:22 PM-->
<!--Modified on: 2/23/2021 12:01:22 PM-->
<xsd:schema targetNamespace="http://protalix.com/20210223" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://protalix.com/20210223">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210223_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210223_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20210223_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2021 12:01:22 PM-->
<!--Modified on: 2/23/2021 12:01:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20210223.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20210223_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/23/2021 12:01:22 PM-->
<!--Modified on: 2/23/2021 12:01:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20210223.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20210223.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637496784827325472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637496784827325472" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637496784827325472" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637496784827325472" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637496784827325472" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637496784827325472" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637496784827325472" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637496784827325472" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637496784827325472" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637496784827325472" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637496784827325472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCountry_637496784827325472" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637496784827335459" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637496784827335459" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637496784827335459" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637496784827335459" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637496784827335459" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637496784827335459" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637496784827335459" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637496784827335459" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637496784827335459" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637496784827335459" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637496784827335459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637496784827335459" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637496784827345450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637496784827345450" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plx-20210223x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210223.xsd" xlink:type="simple"/>
    <context id="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-02-23</startDate>
            <endDate>2021-02-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_1nsKhS4p3UGjAmBFLAY_Kg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_BGWTED7tykauGVSulTz3sQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_zhrRaXm2P0CPqBvRtevE0w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_RbKN5T7o-EG2f9iW9x2fHg">2021-02-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_Rh3QZzYL00CcEPWqzxA4mA">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_gw-3MT-dH0a5aJ2ZA8Pngw_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_iEoNX6d_406ylrWyl9nvlA_0_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_XhcHPPhAG06NgJQHvALf0Q_0_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_k7Wv8i8zDUiNy059Y6ga2Q_3_0">2 Snunit Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_g-alXcnZdESXLQTDrj738Q_4_0">Science Park, POB 455</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_ydDTsa2-qUS6ZTT1TYZgKA">Carmiel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_oquK1Wyl7U2U61YVYFhC-w">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_CmCgRNitN02IlwUt7Yb7Dg_5_4">2161401</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_5VMagqk5FEyKG-X233Zj8Q">972-4</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_agM8SDy8EUugWleHBjy7bg">988-9488</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_7Q0pKDIn7kaCBomAlnHP0w">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_OQzerhduw0elgA5g4r8D7A">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_LlwwebT99EWir3n2BnSeiw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_kJ2UqQqUfE-nGjnjlM2x0w">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_eDokBOTHqUCLh7Yaoox2zw_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_lqiXCmV2D0mGXfhWQ04xHA_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Tc_eJg70SAC0ESS_HoOlRIKEA_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA"
      id="Narr_nJXQIXw_5kSF3sg0Jqc-5g">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139906629491096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 23,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Snunit Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Science Park, POB 455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmiel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2161401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">988-9488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ ,3A74B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ ,3A74@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  Q.%=2X$W"%^X    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( #$X5U(<.&7J/P$  #P"   /
M  "  84/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  Q.%=2)!Z;HJT
M  #X 0  &@              @ 'Q$   >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  Q.%=299!YDAD!  #/ P  $P
M@ '6$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   @$P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20210223x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20210223x8k.htm">plx-20210223x8k.htm</File>
    <File>plx-20210223.xsd</File>
    <File>plx-20210223_lab.xml</File>
    <File>plx-20210223_pre.xml</File>
    <File>plx-20210223xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210223x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20210223x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210223_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210223_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210223.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20210223",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210223x8k.htm",
      "contextRef": "Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210223x8k.htm",
      "contextRef": "Duration_2_23_2021_To_2_23_2021_hq-iAGBUsUKoOHECNUsXeA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20210223",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-21-001407-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-001407-xbrl.zip
M4$L#!!0    ( #$X5U+)8?G2L@,  ,4,   0    <&QX+3(P,C$P,C(S+GAS
M9+57VV[C-A!]+]!_X.I=HB1O-K419['IMD6 I"VR*9"W!4W1-E&)5$DJ=OY^
MAQ2I^$(YWJ)]LLPY,W/F*NKJX[:IT3-3FDLQ3XHL3Q 35%9<K.9)IU.B*>?)
MQ^L??[AZEZ9/-P]WJ)*T:Y@PB"I&#*O0AILU>I1M2P2Z9TKQND8WBE<KAM T
M^Y!=7A:3['W^_F*"TM1;NB$:-*5 SF29%8/D9V]5BADJ<3G!95X6J"AG>3$K
M2_3G_8"\!YI+_C9TJZN9IFO6$&2(6C'S.VF8;@EE\V1M3#O#N%72D)IO,RH;
M9R4ORTF"B#&*+SK#?I6J^<R6I*L-I$7\TP'8NH9LU<PF8P^P(X;T"CT#!H.K
MS6:3;2:95"MPE!?XZ?[NBR,7P%P\,VT&_':AZDPSFJWD,^YEH%A,TKQ()T50
MJAB/:X# PJ?[<*CLBI!V4%D2O7"4O""BHI5)S4O+]+'2((I[4K*.:05)1$FQ
MY5Z^7$0^8Q\P2(?$@J ZR)7'7>!>&*!""M$U<;.54=@&@ &4 HHI3H,>[92"
MD7B)IS=(;1"7^T%LZ]$8)OCICHN_!VJ$4QVW[T01XS;E(WD=1)'$4MD)H\9B
MZ841;YU1H[%,,4AW:$4)1:C4D( 3";+B!2R) &=;NH[3MI*(_3.*O5_H[1$C
M/Z;%=#K%3CJ$R6F<"P@LE>)H!D8F)TAB_-G*[L$3>;=%QAXV,#.M&J$&$NOF
MIWTW9ZRXL,/XVSLLY4(;(BC;'5!^HLR'^+;>OK&48:,CY'8Z$0( !MY<[BR<
MMBT72^F/X- 6;F9S]0B91O;AKX?;N!.7T<_^_19^/XGJ%V&X>;D%LZIQ#A/$
MH3)G(0<B@4K%EEQP1SN',N8H1<' [B,1%>JMH1US5_C0QJ'Y#EZL?XAK]]PJ
MIL&6T[0+QVM[R"E-2FK:U?]"\979N)X_#34Y*%68_ >V1&[J9G9$YHGF35O;
M1G%G:_>.@'9)0V=\A6@SZ** L.9/=)ZK]6&"O-]@@BAZ9.5H*=@6:IDR',;X
M=6OA_RJJFBR^-RI08?7_$\X5/IPQ?[(_BVX2(3*I#!)'MZU3:Z"_J-U)ZHR=
M4+'_AG63VJ.T*&&Q9> Z\#U-(WY;.)- 4+">+[[3Y]C=+.9:CRG9A_15^XB"
MOY@Z#J^K*K:B/BVT482:?JE!\WT]#]TWL-OP\-Y1\,EP:UAC)QI"Z0#&36<U
M?E.R:P.0 P0NUM[(/#&J [B ;P:RL*W9_^^QT(9<5H_.3=4IOWEMC'W3]?FZ
M_@902P,$%     @ ,3A74A4C] .@!0  /S\  !0   !P;'@M,C R,3 R,C-?
M;&%B+GAM;-6;[V_B-AS&WT_:__ =]V:3+H2$NYV*VIXH=S=5H]?J8-IITW0*
MB0%KP4:..>A_/SN)@02;GUTP;]HT?OSX^YA/G(2DU^\7DQB^(Y9@2FYJ7KU1
M T1"&F$RNJG-$B=(0HQK[V]__.'Z)\?Y>O>E"Q$-9Q-$.(0,!1Q%,,=\#'TZ
MG08$'A!C.([ACN%HA "NZK_6W[WSFO4WC3=OF^ XN=-=D(B>E$!JZ=>]94LG
M=Z6D!;[K-UV_X7O@^:V&U_)]>'I8*A]$F4.\6QIC\F]+_AB(04$$)DEKD>";
MVICS:<MUY_-Y?=ZL4S82!@W/_?K0[85C- D<3!(>D!#50.A;2;JS2\. I[.U
MUGTQ8+$R:+K+L8P*^9>C9([<Y7B^T_3JBR2JY27*YCT&47+9&O%EAW7Q6S=K
M7$HWK//XWM75E9NVUL3$ >13%PQ0W!5;D#:U^/,4W=30@B,2(5ENNI?1&&TI
M5S:[*V?I3<."82PGEC+E-V9H>%.;Q@M'?JH-WV_*R7DE=GS[D!/8)M%'PC%_
MOB=#RB;IQ](>))P%(5<V:?&IS[[=Y!3M->_N,HD<H\V*<0(6JAK$YH[9R15N
M2 5M4^ZDCJK[D-')00FR*NC^?;[%@_CXY(78#"5TQM)#9G\LUM,>^($M2Q<=
MY9J%B/-'[X LMVH0"$@$V3"P-@[\K4;ZYSHK]"!^90&).AP3%-9']+L;(2RJ
M\*[DAB,WG(:7'_ROQ*YE[K[P+4V+IME27DU!))?E-@OY,Y9X,F?2K7*4GA##
M5!Q%T0=Q<MT2M:R[ +BTT<J4%426XZ:O]63N,ENQQ$4@C2M#,%M3/^$8?9Y-
M!HAIDFLD%H-G"J28*[=;BINQS&-)RT^>TA$RRXH9^X)&6)ZK"?\<3'2KG$%F
M/6OZ8$7>BAJKF3.4>B)W*U>0MA6S=R_NFMF4LO2BL<?% MNA,\+9<X=&9A1W
M];*>S+UB%T'=VL5J;O>K_$2,"X.\AG08H SRH4".53';_6!Q'XE+"#S$V7<?
M.T[D9KWU/.^(6B39(+::X5TUGTBOL(>B_WDN!=I1).8NR7]U,4&><4KT6NM1
MW1*QB*E&:#6BV^H]$<_<\[7: .D.CZ3J%74SHG_ =/B7B:>_+Y[^A>'I_P]X
MKNCLS^EYZ.R(S4?6IW.R:RX*RDLA<S.>ELN5[!*HU%3[4DQ*:WDA*LW/ ^03
M37@0_X6G6^^I#.)+P5(;4DMF07D)<.H+?BD^,W<0]N>X1U+'7W:7MO,P7<HN
M!<M2,/U2F6DN <5RJ2^V2&:^E<$G%^4V0X%A12PU6PR;+HB";+W-4KBT)1X+
M57JFE6[5+F3RS9;X:4R)^4&-1F(Q4Z9 BJMRNZ5L&<L\EJ_4$%+'JK^=^9-A
MSA'IT,ED1O)OB!)-9I/.8MJV1E/(:466<K>]UF/ARUVA:%L9@#T:XQ!S3$8/
M 4<,![KD6I'%Z)E#*>XV%99"MZ708XE;68+RK RW)X8DZ$A\?.F;1/*52?8X
M'&K/KEO%%N.W.Z3"T*RT%,<]"CX62V'MA&O>D)E#ZGXN0.^39(;809CJNEP.
MK,; !F0W])<!KKGL%\,W&^(\%/=0.!/7%<^>/^AC'NMNA342BRDU!5J>STOM
MEE)H+/-8ZE(7H$/P_)\'OX#RKPRT/@OD_\;TGB<#J@M<;K<8,6T4Q5>AT5*X
M]#4>35;F!IE=Y2O7QT4X%H4CPYN+!IG%>&T+5E[%UC66PK:UU*/O3')34*[G
M>'/QXP2QD2#_-T;G?"PN&J8!,3_ ,*DM)G&/F,7'&5JII5SN4_&)#S>4.63N
MD-M7C&E'7&.R(+X75Y>+WY$9T$V=]6@:HA6A+(FLQM%4ZXD@YK:0^H(PK@S!
MMKC#B>1=SJ<X&&EBE]LM1DX;1:%6:+04,7V-QZ*U= -IMP[4M;L:N2NVY+^2
MY[ORWK?_ 5!+ P04    "  Q.%=2J6NXIY@$  #'*@  %    '!L>"TR,#(Q
M,#(R,U]P<F4N>&ULW9KOCZ(X&,??7W+_0X]]C?S2<33C;AQW]F)V9G<RX^4V
M]V93H6ISI26EKLY_?RU25P4$[Q(Y>*/8?GEXOOV4"@_<?=B&!/Q /,:,C@RG
M8QL 49\%F"Y'QCHV8>QC;'QX_^LO=[^9YK?[ET<0,'\=(BJ SQ$4*  ;+%9@
MQJ((4O"$.,>$@'N.@R4"8-"YZ?3[CM?IVMV>!TPSC70/8[DGHR )Z7:<?<\D
MC<KH$+B6ZUFN[3K <8>V,W1=\/RT5S[)-!>X7$HP_7NH/N;RH$ :IO%P&^.1
ML1(B&EK69K/I;+P.XTL9P':L;T^/K_X*A=#$-!:0^L@ 4C^,D\9'YD.1C-;!
M[MLY)SJ 9^V/5:A0OTPM,U63Z;BFYW2V<6"D*:KN"@?1<M6+S^@/O.STF?CI
M&#B#P<!*>@TY>@#<<4;0"UJ I&THWB(T,F(<1D3%2MI6'"U&1D2VIB)@NZZG
MC+S[F,X4_3VFP0,56+Q-Z8+Q,!E& ZCP?[Q,]ZE$G E(\+;CL]!2G5:U.(FM
M2@-F[7Q%',4R6K+[H^Q,S:A#_O=D#L8*;06B 0KVK5BH(]BV/;"!"72@PTU(
M ["+"OZ=Q\2A]$B8?Y0+4;.7\1)PLN'[.7_C>2PX](4.0^ <D21.Q=VLB_)3
M=F/I-_$:([^S9#^L &'IV1FH#5-MF+:3GD'O9-,^D9F,>Y+G:??W&Z_?'=ST
M;[NW;M]S>]V^>Y#BX309\^-T(?=U;+EY-'.R<%*%%4$NXYG^"I/]G%AP%EXR
M@&D2K*(9Q@/$Y?IN@'4L4V21B@;)54$\(XZ9]!1\E.O[&2)'NM:@*7>5,G+K
M8+2S\PD3]&4=SA'/P7,J:3R92H92*%Y]4%[0$BL#5'R!8=YYDR=K"9P*IE)
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M6M@WV<MASLK=E5M6;2*E\]>9+E98MMFJ.(*"&D[@6#YJ^)00_R_Q\)*Z^"&
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M=P@&'SZ#^R&4E'K$N$%L'Q$>#*@+-A3+)=+=,=*)[8Z8U-A-)ML0=7+",>H
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M7J@^&T$U WL"QF3 [%)N"(;[7E@S.OC7P K^0EON,>BD!Y8U,^A813S?,BK
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M2G/#BD/7,N='%>_].]TU)_"OY_?MO?\'4$L#!!0    ( #$X5U(^J_Z^AAT
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MO?YP^>8/-^IJBI>^^V;PO']\>7FIWL]-WGVK1R;KJ&N@T63:?0_Y5Z<8@'0
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MF%]+,)F2 W.J88,?)O>B61P:IEU73&  QG J56'JOA7QM"!#D=6B=FO3W"Q
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M(+G54V9\/*IU,FS)'%)8$LX)4I:U+\W-#>2K3YU)JV<CA,O58)*X0O+<*25
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M2P$"% ,4    "  Q.%=2DDF,K684  #-B0  $P              @ %\#@
M<&QX+3(P,C$P,C(S>#AK+FAT;5!+ 0(4 Q0    ( #$X5U(^J_Z^AAT  $ME
M   7              "  1,C  !P;'@M,C R,3 R,C-X97@Y.60Q+FAT;5!+
4!08     !0 % $@!  #.0      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
